DRI Healthcare Trust (TSE:DHT.UN) Stock Price Up 0.1% – Here’s Why

DRI Healthcare Trust (TSE:DHT.UN) shares traded up 0.1% during trading on Thursday. The stock traded as high as C$19.17 and last traded at C$18.77. 48,368 shares were traded during mid-day trading, a decline of 9% from the average daily volume of 53,404 shares. The stock had previously closed at C$18.75.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. National Bank Financial lifted their target price on DRI Healthcare Trust from C$23.50 to C$25.50 and gave the company an “outperform” rating in a research note on Tuesday, September 22nd. Stifel Nicolaus increased their price target on DRI Healthcare Trust from C$25.00 to C$26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of C$25.60.

DRI Healthcare Trust Stock Performance

The stock has a market cap of C$1.03 billion, a price-to-earnings ratio of -23.46 and a beta of 0.09. The company’s 50 day simple moving average is C$17.96 and its 200 day simple moving average is C$17.32.

DRI Healthcare Trust Company Profile

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.